Literature DB >> 26980047

The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study.

Francisco Diaz-Crespo1, Javier Villacorta2, Mercedes Acevedo3, Teresa Cavero4, Carmen Guerrero5, Eugenio García Díaz3, Juan Luis Orradre6, Miguel Angel Martinez7, Manuel Praga4, Gema Fernandez-Juarez2.   

Abstract

The histopathologic classification of antineutrophil cytoplasmic antibody-associated vasculitis has been demonstrated to have prognostic value in small cohorts of patients with pauci-immune extracapillary glomerulonephritis. We aimed to validate this histologic subgrouping system in a large cohort of patients with renal vasculitis from 3 Spanish centers. The additional value of several histologic parameters for predicting renal outcome was investigated. A total of 151 biopsies of patients with renal vasculitis were reviewed and classified as follows: 41% crescentic, 24% mixed, 21% focal, and 14% sclerotic. The cumulative proportions of renal survival at 5 years were 83.2%, 81.2%, 60.5%, and 50.7% for the focal, mixed, crescentic, and sclerotic categories, respectively (P < .05). In the crescentic category, patients with less than 75% of glomeruli showing crescents had better survival at 1 and 5 years compared with those having greater than or equal to 75% of crescents (77.9% and 70.6% versus 51.3% and 45.6%; P = .02). When adjusted by renal function and other histologic parameters, the percentage of extracapillary proliferation and glomerulosclerosis remained as significant predictors for renal survival (hazard ratio, 1.03; 95% confidence interval, 1.01-1.05; P = .001, and hazard ratio, 1.03; 95% confidence interval, 1.01-1.05; P = .002, respectively). In conclusion, patients with pauci-immune crescentic glomerulonephritis experienced different outcomes depending on the percentage of crescents observed, so that extensive extracapillary proliferation was associated with the poorest renal survival. These findings validate the prognostic utility of the histologic classification scheme in antineutrophil cytoplasmic antibody positive and negative patients and suggest a subdivision of crescentic category (<75% and ≥75% of crescents) based on the different survival rates observed among these subgroups.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antineutrophil cytoplasmic antibody; Crescent; Glomerulonephritis; Kidney; Vasculitis

Mesh:

Substances:

Year:  2016        PMID: 26980047     DOI: 10.1016/j.humpath.2016.01.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study.

Authors:  L García; C E Pena; R Águila Maldonado; C Costi; M Mamberti; E Martins; M A García
Journal:  Clin Rheumatol       Date:  2019-06-20       Impact factor: 2.980

2.  Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement.

Authors:  H Marco; J Draibe; J Villacorta; L F Quintana; N Martin; R Garcia-Osuna; C Cabre; M A Martín-Gómez; A Balius; A Saurina; M Picazo; I Gich-Saladich; M Navarro-Díaz; M Praga; T Cavero; J Ballarin; M M Díaz-Encarnación
Journal:  Clin Rheumatol       Date:  2018-03-09       Impact factor: 2.980

3.  Clinical, serological and histological determinants of patient and renal outcome in ANCA-associated vasculitis with renal involvement: an analysis from a referral centre.

Authors:  Matija Crnogorac; Ivica Horvatic; Luka Toric; Danica Galesic Ljubanovic; Miroslav Tisljar; Krešimir Galesic
Journal:  Int Urol Nephrol       Date:  2017-06-23       Impact factor: 2.370

4.  Interest of a Kidney Biopsy to Rule out ANCA-Associated Renal Vasculitis in Glomerulonephritis Patients with a Positive ANCA.

Authors:  Florian Garo; Cédric Aglae; Hélène Perrochia; Pedram Ahmadpoor; Laurent Daniel; Olivier Moranne
Journal:  Case Rep Nephrol Dial       Date:  2022-04-28

Review 5.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

6.  Circulating C3 levels predict renal and global outcome in patients with renal vasculitis.

Authors:  Javier Villacorta; Francisco Diaz-Crespo; Mercedes Acevedo; Teresa Cavero; Carmen Guerrero; Manuel Praga; Gema Fernandez-Juarez
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980

Review 7.  An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a Bayesian network meta-analysis.

Authors:  Shanshan Huang; Qing Shen; Ruoqing Yang; Heng Lai; Jing Zhang
Journal:  Int Urol Nephrol       Date:  2018-07-25       Impact factor: 2.370

8.  Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome.

Authors:  Matija Crnogorac; Ivica Horvatic; Patricia Kacinari; Danica Galesic Ljubanovic; Kresimir Galesic
Journal:  J Nephrol       Date:  2017-10-13       Impact factor: 3.902

Review 9.  Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis.

Authors:  Emma E van Daalen; Maria A C Wester Trejo; Arda Göçeroğlu; Franco Ferrario; Kensuke Joh; Laure-Hélène Noël; Yayoi Ogawa; Suzanne Wilhelmus; Miriam J Ball; Eva Honsova; Zdenka Hruskova; Renate Kain; Tomoyoshi Kimura; Marek Kollar; Andreas Kronbichler; Kristine Lindhard; Xavier Puéchal; Steven Salvatore; Wladimir Szpirt; Hideki Takizawa; Vladimir Tesar; Annelies E Berden; Olaf M Dekkers; E Christiaan Hagen; Jan Oosting; Chinar Rahmattulla; Ron Wolterbeek; Willem Jan Bos; Jan A Bruijn; Ingeborg M Bajema
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-28       Impact factor: 8.237

10.  Long-term validation of the renal risk score for vasculitis in a Southern European population.

Authors:  Javier Villacorta; Francisco Diaz-Crespo; Carmen Guerrero; Mercedes Acevedo; Teresa Cavero; Gema Fernandez-Juarez
Journal:  Clin Kidney J       Date:  2020-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.